DBCO-PEG4-VC-PAB-MMAE consists a ADC linker (DBCO-PEG4-VC-PAB) and a tubulin polymerization inhibitor MMAE (HY-15162). DBCO-PEG4-VC-PAB-MMAE can be used in the synthesis of antibody-agent conjugates (ADCs). MMAE is a synthetic derivative of dolastatin 10 and functions as a potent mitotic inhibitor by inhibiting tubulin polymerization. DBCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.

THP-PEG1-alcohol is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs.

HCQ-2 NHS is a dark quencher with no native emission due to the polyaromatic-azo backbone and a terminal NHS ester. UBHQ-2 NHS has a wide and intense quenching range from 560-670 nm, which makes it useful as an acceptor in fluorescence resonance energy transfer (FRET) applications in conjunction with orange to far-red emitting dyes. The NHS ester can be applied to label the primary amines (-NH2) of proteins, amine-modified oligonucleotides, and other amine-containing molecules.

JP-11646 is a novel potent, selective, non-ATP competitive Pim2 inhibitor with IC50 of 0.5/1/24 nM for Pim2/3/1, respectively; shows less potency for other kinases in a kinase selectivity panel; exhibits 4-760-fold greater suppression of MM proliferation and viability than ATP-competitive PIM inhibitors; significant reduces tumor burden and increases median survival in xenogeneic myeloma murine models.

Allopole prodrug moiety is the prodrug form of Allopole.

Allopole-A-octyl diamine derivative is the prodrug of Allopole-A.

Thalidomide-O-PEG4-amine is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology.

RAP-103 is an orally active, stabilized pentapeptide analog of DAPTA (D-ala-peptide T-amide), and multi-chemokine receptor antagonist.

QD325 is a potent redox modulator that induces Nrf2-mediated oxidative stress and unfolded protein responses in PDAC cells (IC50=0.9 uM).

BSJ-05-037 is a potent and selective heterobifunctional degrader of ITK with DC50 of 17.6-41.8 nM in TCL lines DERL-2 and Hut78. BSJ-05-037 induces potent degradation of ITK dependent on CRBN, neddylation, and the proteasome. BSJ-05-037 induces GATA-3 loss and decreases chemotherapy resistance in vitro. BSJ-05-037 disrupts TCR signaling, downregulates the Th2-associated transcription factor GATA-3, and can overcome chemotherapy resistance in TCL models in vivo.

Novel selective inhibitor of the transient receptor potential melastatin 2 (TRPM2) channel, exhibiting TRPM2 selectivity over TRPM8 and TRPV1 channels as well as phospholipase A2 and showing neuroprotective activity in vitro, and significantly reducing ce

76-O17Se is a lipidoid for the efficient delivery of antiCD19 mRNA CAR to murine primary macrophages. 76-O17Se is more efficient than delivery with lipofectamine 2000 (LPF2K) or MC3

BAmP-TK-12 is a ROS-responsive ionizable lipid designed for tumor-cell mRNA delivery. It features a bis(aminopropyl)piperazine-derived ionizable headgroup and four C12 tails connected through cleavable thioketal linkers. In the reported study, BAmP-TK-12 achieved RFP expression in up to 95% of HeLa cells, comparable to Lipofectamine 3000, with lower cytotoxicity under the tested conditions. ROS-triggered linker cleavage supported intracellular mRNA release in high-ROS tumor cells. When formulated with DUF5 mRNA, the LNP suppressed tumor growth in HCT-116 and A549 xenograft models, supporting its use as a promising preclinical research lipid for stimulus-responsive mRNA delivery.

ML385 is a novel and specific NRF2 inhibitor.

IDE-1 induces definitive endoderm formation in mouse and human embryonic stem cells (ESCs) (EC50 = 125 nM).

DOTA-ADIBO TFA is a DOTA-derived bifunctional chelator (BFC) that allows drug conjugation via an uncatalyzed, copper-free cycloaddition reaction. DOTA-ADIBO TFA enables the construction of fusion chelator systems that can be further used to synthesize radiotracers after Cu[64] modification. Positron emission tomography imaging of tumors expressing integrin αvβ6.

LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor, enhance Emax but without affecting agonist potency.

Antagonist of central cholecystokinin receptors

DSG-PEG3400-Mal is a conjugate composed of DSG, PEG chains, and maleimide (Mal). The maleimide group in DSG-PEG3400-Mal can undergo a specific Michael addition reaction with thiol-containing (-SH) biomolecules (such as peptides, antibodies, and aptamers), enabling targeted modification of liposomes/nanoparticles.

DSG-PEG3400-N3 is a conjugate composed of DSG, PEG chains, and terminal azido groups (-N3). DSG-PEG3400-Azide is a click chemistry reagent used for the targeted modification of liposomes/nanoparticles.

TYRA-300 is the first oral selective FGFR3 inhibitor with IC50 of 11 nM in Ba/F3 cells, and shows selectivity over FGFR1, FGFR2 and FGFR4 in Ba/F3 cells was 25-, 14-, and 36-fold, respectively. TYRA-300 demonstrates equivalent potency for FGFR3 WT and V555M/L gatekeeper mutations in enzymatic assays and in engineered RT112/84 and UM-UC-14 bladder cancer cell lines containing the V555M mutation.